Home / Deep Research / Diabetic Retinopathy

Diabetic Retinopathy

1. Disease Information

2026-06-16
Falcon MONDO:0005266 Model: Edison Scientific Literature 48 citations

1. Disease Information

1.1 What is the disease?

The American Diabetes Association (ADA) Standards of Care describes DR as “a highly specific neurovascular complication of both type 1 and type 2 diabetes,” whose prevalence is strongly linked to diabetes duration and glycemic control. (elsayed202512.retinopathyneuropathy pages 1-1)

The International Council of Ophthalmology (ICO) guideline describes DR as “the most common specific microvascular complication of DM,” progressing from milder nonproliferative diabetic retinopathy (NPDR) to vision-threatening proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME). (wong2018guidelinesondiabetic pages 2-3)

1.2 Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

Within the tool-accessible corpus retrieved for this report, explicit ontology identifiers (MONDO ID, MeSH ID, ICD-10/ICD-11 codes, OMIM, Orphanet) were not available as citable evidence; therefore, they cannot be verified here and should be populated from external ontology resources (e.g., MONDO, MeSH, ICD-10/ICD-11 browsers). (No in-corpus evidence)

1.3 Synonyms and alternative names

Common clinical terms in guidelines and recent literature include: - Diabetic retinopathy (DR) (wong2018guidelinesondiabetic pages 2-3) - Nonproliferative diabetic retinopathy (NPDR) (wong2018guidelinesondiabetic pages 2-3, elsayed202512.retinopathyneuropathy pages 2-3) - Proliferative diabetic retinopathy (PDR) (wong2018guidelinesondiabetic pages 2-3, elsayed202512.retinopathyneuropathy pages 2-3) - Diabetic macular edema (DME) (wong2018guidelinesondiabetic pages 2-3) - Clinically significant macular edema (CSME; classic ETDRS term) (elsayed202512.retinopathyneuropathy pages 3-4)

1.4 Evidence source type

This report is derived from aggregated disease-level resources (international guidelines, systematic reviews, meta-analyses, epidemiologic studies, and clinical trial registry records) rather than individual-patient EHR-derived phenotypes. (wondmeneh2024prevalenceofdiabetic pages 12-15, wong2018guidelinesondiabetic pages 2-3, elsayed202512.retinopathyneuropathy pages 1-1, NCT02471651 chunk 1)

2. Etiology

2.1 Disease causal factors (mechanistic)

The etiologic driver is chronic diabetes-associated metabolic dysregulation (particularly hyperglycemia) leading to neurovascular retinal injury through oxidative stress and inflammatory pathways. Mechanistic reviews synthesize the cascade: hyperglycemia activates metabolic pathways (e.g., AGE formation, PKC activation), promoting ROS generation and inflammatory signaling, damaging pericytes/endothelial cells and destabilizing the BRB, which contributes to macular edema, ischemia, and neovascularization. (gomezjimenez2025modulationofoxidative pages 7-8, srejovic2024molecularandcellular pages 1-3, srejovic2024molecularandcellular pages 3-4)

2.2 Risk factors (human epidemiology)

ADA (risk-factor framing): DR prevalence relates strongly to diabetes duration and glycemic control, with additional associated factors including chronic hyperglycemia, nephropathy, hypertension, and dyslipidemia. (elsayed202512.retinopathyneuropathy pages 1-1)

Recent meta-analysis (Ethiopia, 2024): pooled DR prevalence in adults with diabetes was 24.35% (95% CI: 18.88–29.83), with key risk factors: - Diabetes duration ≥10 years: AOR 4.36 - Hypertension: AOR 2.54 - Poor glycemic control: AOR 3.83 - Positive proteinuria: AHR 1.55 (wondmeneh2024prevalenceofdiabetic pages 1-2, wondmeneh2024prevalenceofdiabetic pages 12-15)

2.3 Protective factors

Direct evidence for protective genetic variants or protective exposures was not captured in the retrieved corpus. The ADA/ICO guidelines emphasize risk reduction via achieving glycemic, blood pressure, and lipid targets, which functionally serve as protective measures against onset/progression. (wong2018guidelinesondiabetic pages 2-3, elsayed202512.retinopathyneuropathy pages 1-1)

2.4 Gene–environment interactions

Not explicitly quantified in the retrieved corpus. Mechanistic syntheses support an interaction model in which systemic metabolic exposures (hyperglycemia, dyslipidemia, hypertension) modulate inflammatory/oxidative pathways and vascular signaling (e.g., VEGF), which in turn shape disease expression. (gomezjimenez2025modulationofoxidative pages 7-8, srejovic2024molecularandcellular pages 1-3)

3. Phenotypes (clinical manifestations)

3.1 Core phenotypes and staging (ICO clinical taxonomy)

ICO describes DR microvascular lesions including “microaneurysms, intraretinal hemorrhages, venous beading…, intraretinal microvascular abnormalities, hard exudates…, and retinal neovascularization.” It also highlights that early DR is often asymptomatic and that advanced DR/DME can exist without visual symptoms. (wong2018guidelinesondiabetic pages 3-5)

DR staging terms: - No apparent DR → mild/moderate/severe NPDR → PDR (wong2018guidelinesondiabetic pages 2-3) - Key distinction: “Eyes with NPDR have not yet developed neovascularization.” (wong2018guidelinesondiabetic pages 3-5)

DME phenotypes and subtypes: ICO DME classification is explicitly defined by central macular involvement: - Nonecenter-involving DME: macular thickening not involving central 1 mm subfield - Center-involving DME: thickening involving central 1 mm subfield (wong2018guidelinesondiabetic pages 2-3)

CSME definition (ETDRS term used in ADA 2025): “retinal edema located at or threatening the macular center.” (elsayed202512.retinopathyneuropathy pages 3-4)

3.2 Suggested HPO terms (non-exhaustive; to be validated against HPO)

Because explicit HPO IDs are not provided in the retrieved sources, the following are suggested concept-level mappings: - Decreased visual acuity; visual impairment (supported by burden statements and DME context) (elsayed202512.retinopathyneuropathy pages 3-4, elsayed202512.retinopathyneuropathy pages 1-1) - Retinal hemorrhage / intraretinal hemorrhage; microaneurysm; retinal neovascularization (ICO lesion descriptions) (wong2018guidelinesondiabetic pages 3-5) - Macular edema / retinal edema (DME/CSME definitions) (elsayed202512.retinopathyneuropathy pages 3-4, wong2018guidelinesondiabetic pages 2-3)

3.3 Quality of life impact

ADA notes population-level functional consequences: in the U.S., ~12% of adults with diabetes have some level of vision impairment, and diabetes increases risk of chronic vision loss and functional decline. (elsayed202512.retinopathyneuropathy pages 3-4)

4. Genetic / Molecular Information

4.1 Genetic architecture (current evidence availability)

The retrieved evidence set does not provide validated causal germline variants or a curated list of DR causal genes with OMIM IDs; DR is generally treated as a complex complication with multifactorial etiology in this corpus. (No in-corpus variant evidence)

4.2 Disease–target associations (Open Targets)

Open Targets identifies disease–target associations for “diabetic retinopathy,” including VEGFA and PGF (among others such as ANGPT2 and NR3C1), with evidence including clinical-stage associations and literature links. (OpenTargets Search: diabetic retinopathy)

Interpretation: These targets align with established therapeutic biology (anti-VEGF agents; emerging Ang-2/Tie2 biology), but Open Targets associations are not equivalent to confirmed causal germline genetics. (OpenTargets Search: diabetic retinopathy, srejovic2024molecularandcellular pages 1-3)

4.3 Epigenetics / metabolic memory

Mechanistic reviews describe persistent oxidative/inflammatory signaling and “metabolic memory” concepts, where prior hyperglycemic exposure can sustain downstream pathology even after improved glycemia. (gomezjimenez2025modulationofoxidative pages 7-8)

5. Environmental Information

5.1 Non-genetic contributing factors (lifestyle/clinical)

Key modifiable systemic exposures emphasized in guidelines and epidemiology include chronic hyperglycemia, hypertension, dyslipidemia, and nephropathy/proteinuria. (wondmeneh2024prevalenceofdiabetic pages 1-2, elsayed202512.retinopathyneuropathy pages 1-1)

5.2 Infectious agents

Not applicable based on retrieved evidence. (No in-corpus evidence)

6. Mechanism / Pathophysiology

6.1 Causal chain (integrated model)

A coherent causal chain supported across mechanistic reviews is: 1) Diabetes-associated hyperglycemia and metabolic dysregulation 2) Activation of oxidative stress and inflammatory pathways (ROS generation; NF-κB signaling) 3) Retinal vascular dysfunction (pericyte/endothelial injury; tight junction disruption) 4) BRB breakdown → increased vascular permeability → macular edema (DME) 5) Capillary closure/ischemia → pro-angiogenic signaling (VEGF) → neovascularization (PDR) (gomezjimenez2025modulationofoxidative pages 7-8, srejovic2024molecularandcellular pages 1-3, srejovic2024molecularandcellular pages 3-4)

6.2 Key pathways and molecular mediators

6.3 Cell types and ontology suggestions

Cell types (suggested CL concepts; IDs not available in corpus): - Retinal pericytes (pericyte loss emphasized) (srejovic2024molecularandcellular pages 1-3) - Retinal vascular endothelial cells (vascular dysfunction; BRB breakdown) (srejovic2024molecularandcellular pages 1-3, srejovic2024molecularandcellular pages 3-4) - Microglia (activation; inflammatory milieu) (srejovic2024molecularandcellular pages 1-3) - Müller glia (implicated in inflammasome/pyroptosis pathways in mechanistic review synthesis) (gomezjimenez2025modulationofoxidative pages 7-8)

GO biological process concepts (suggested): angiogenesis, inflammatory response, response to oxidative stress, regulation of vascular permeability, cytokine-mediated signaling pathway. (gomezjimenez2025modulationofoxidative pages 7-8, srejovic2024molecularandcellular pages 1-3)

7. Anatomical Structures Affected

7.1 Organ/tissue localization

Primary affected structure is the retina, including the macula (DME) and retinal vasculature (NPDR/PDR). BRB components are explicitly discussed (inner BRB via retinal vascular endothelium; outer BRB via RPE in general retinal vascular disease frameworks). (srejovic2024molecularandcellular pages 1-3, wong2018guidelinesondiabetic pages 2-3)

Suggested UBERON concepts (IDs not available in corpus): retina; macula; retinal blood vessel; vitreous body (relevant to vitreous hemorrhage and tractional detachment risk in PDR context). (wong2018guidelinesondiabetic pages 3-5, simmonds2024antivegfdrugscompared pages 25-27)

7.2 Laterality

DR is typically bilateral (diabetes-related systemic exposure), but explicit laterality assertions were not provided in the retrieved corpus. (No in-corpus evidence)

8. Temporal Development

8.1 Onset pattern

ICO emphasizes that DR “develops over time” and that early disease may be asymptomatic, supporting an insidious onset. (wong2018guidelinesondiabetic pages 2-3, wong2018guidelinesondiabetic pages 3-5)

8.2 Progression

ICO explicitly frames progression from NPDR to PDR/DME and notes that PDR is an angiogenic response to extensive ischemia from capillary closure, consistent with stepwise worsening in untreated disease. (wong2018guidelinesondiabetic pages 2-3)

9. Inheritance and Population

9.1 Epidemiology (recent statistics)

9.2 Inheritance pattern

Not applicable as a monogenic inheritance pattern in this evidence set; DR is treated as a complex complication. (No in-corpus evidence)

10. Diagnostics

10.1 Screening and diagnostic modalities (guideline-based)

ADA Standards of Care (2025): - Initial eye exam timing: - Type 1 diabetes: “within 5 years after the diagnosis of diabetes” (dilated, comprehensive). (elsayed202512.retinopathyneuropathy pages 2-3) - Type 2 diabetes: “at the time of diagnosis.” (elsayed202512.retinopathyneuropathy pages 2-3) - Follow-up: - Generally annual for none/mild retinopathy; “screening every 1–2 years may be considered” in selected low-risk scenarios after normal exams and if glycemic indicators are at goal. (elsayed202512.retinopathyneuropathy pages 1-2) - Implementation: validated retinal photography programs with trained readers; FDA-approved autonomous AI systems may be used where appropriate (e.g., EyeArt, LumineticsCore, AEYE-DS), but abnormal/ungradable images require in-person eye examination. (elsayed202512.retinopathyneuropathy pages 1-2)

Image evidence: the ADA recommendations box summarizing these screening statements is available as a cropped guideline image. (elsayed202512.retinopathyneuropathy media 6876c524)

ICO (resource-stratified) follow-up intervals (high-resource example): - No apparent DR or mild NPDR (no DME): re-examination in 1–2 years - Moderate NPDR: 3–6 months - PDR: <1 month and DME classification into center-involving vs nonecenter-involving by clinical findings and OCT (if available). (wong2018guidelinesondiabetic pages 7-9, wong2018guidelinesondiabetic pages 2-3)

10.2 Differential diagnosis

Not extracted from the retrieved corpus. (No in-corpus evidence)

10.3 Omics-based diagnostics

Not supported by direct evidence in the retrieved corpus (though mechanistic reviews discuss biomarkers conceptually). (toma2026oxidativestressin pages 1-2)

11. Outcome / Prognosis

11.1 Vision loss and blindness

  • ADA states DR is “the most frequent cause of new cases of blindness among adults aged 20–74 years in developed countries.” (elsayed202512.retinopathyneuropathy pages 1-1)
  • Global DR-related blindness burden has increased substantially over recent decades (1990–2021). (meng2025globalregionaland pages 1-2)

11.2 Prognostic factors

Systemic risk-factor control (glycemia, blood pressure, lipids) is positioned as central to slowing progression, and more frequent ophthalmologic follow-up is required when retinopathy is progressing or in the presence of DME/advanced disease. (elsayed202512.retinopathyneuropathy pages 2-3, elsayed202512.retinopathyneuropathy pages 1-1)

12. Treatment

12.1 Standard-of-care ocular treatments

  • Anti-VEGF therapy is a cornerstone for DME, particularly center-involving DME, and is supported as more effective than laser monotherapy for center-involved DME in ADA discussion. (elsayed202512.retinopathyneuropathy pages 3-4)
  • Panretinal photocoagulation (PRP) remains indicated for high-risk PDR (and selected severe NPDR) to reduce risk of vision loss. (elsayed202512.retinopathyneuropathy pages 2-3)

12.2 Quantitative treatment outcomes (recent syntheses)

Anti-VEGF in DME (systematic review, 2024): proportion gaining ≥15 ETDRS letters ranged 18.1%–44.8%, with central macular thickness reductions commonly in the range of 183.1–294 µm (across DME/RVO cohorts). (Aldokhail et al., 2024; https://doi.org/10.2147/OPTH.S489114) (aldokhail2024outcomesofantivegf pages 1-2)

Trial-based outcomes summarized in 2024 review: ranibizumab RISE/RIDE reported 40–44% gaining ≥15 ETDRS letters vs 20% with sham at 3 years, with CMT reductions about −261 to −269 μm. (Cheema & Cheema, 2024; https://doi.org/10.7759/cureus.52676) (cheema2024diabeticmacularedema pages 5-7)

Real-world implementation challenge: a 2024 review emphasizes that trial vision gains depend on frequent injections/monitoring and that real-world outcomes are often poorer because maintaining frequent injection schedules is difficult. (Nakao et al., 2024; https://doi.org/10.1007/s00417-024-06558-y) (nakao2024antivegftherapyfor pages 1-2)

Anti-VEGF vs PRP in DR (Health Technology Assessment, 2024): network meta-analysis across 14 RCTs found anti-VEGF “slightly better” than PRP for BCVA up to 2 years (mean difference −0.089 logMAR ≈ 3.6 ETDRS letters) and reduced macular edema (RR 0.29; 95% CI 0.18–0.49) and vitreous hemorrhage (RR 0.77; 95% CI 0.61–0.99); authors concluded the BCVA benefit is small and may not be clinically meaningful. (Simmonds et al., 2024; https://doi.org/10.3310/pcgv5709) (wong2018guidelinesondiabetic pages 1-2)

12.3 Systemic therapies and risk-factor modification

ICO and ADA emphasize maintenance of glycemic control and management of hypertension and dyslipidemia as core strategies to reduce risk and slow progression. (wong2018guidelinesondiabetic pages 2-3, elsayed202512.retinopathyneuropathy pages 1-1)

12.4 Examples of recent/ongoing/illustrative clinical trials (ClinicalTrials.gov)

  • NCT06662994 (2025; Phase 4; Recruiting): high-dose aflibercept 8 mg in central-involving DME after prior vitrectomy, using a treat–extend–stop protocol; outcomes include visual acuity and OCT thickness over 12 months. (https://clinicaltrials.gov/study/NCT06662994) (NCT06662994 chunk 2, NCT06662994 chunk 1)
  • NCT02471651 (2015; Phase 4; Completed): dexamethasone intravitreal implant (Ozurdex 0.7 mg) vs continued monthly anti-VEGF for persistent DME after prior anti-VEGF; primary endpoint central 1 mm subfield thickness change. (https://clinicaltrials.gov/study/NCT02471651) (NCT02471651 chunk 1)
  • NCT07144865 (2024; Completed; phase not specified in excerpt): evaluates biological changes in fibrovascular membranes in PDR following faricimab injection (relevant to dual-pathway anti-VEGF/Ang-2 strategies). (https://clinicaltrials.gov/study/NCT07144865) (NCT07144865 chunk 2)

12.5 MAXO suggestions (concept-level; IDs not available in corpus)

  • Intravitreal injection of anti-VEGF agent (elsayed202512.retinopathyneuropathy pages 3-4)
  • Panretinal photocoagulation (elsayed202512.retinopathyneuropathy pages 2-3)
  • Focal/grid laser photocoagulation (macular edema context) (elsayed202512.retinopathyneuropathy pages 3-4)
  • Vitrectomy (vision-threatening complications context in ICO) (wong2018guidelinesondiabetic pages 1-2)

13. Prevention

Primary/secondary prevention framing: DR is preventable and progression-reducible through systemic risk-factor control and systematic screening programs. - ICO explicitly states that “Vision loss from DR can be prevented with broad-level public health strategies,” and both ICO and ADA emphasize glycemic and cardiovascular risk control. (wong2018guidelinesondiabetic pages 1-2, elsayed202512.retinopathyneuropathy pages 1-1) - ADA screening intervals (type 1 within 5 years; type 2 at diagnosis; generally annual thereafter with risk-stratified extension to 1–2 years) operationalize secondary prevention via early detection and timely referral. (elsayed202512.retinopathyneuropathy pages 2-3, elsayed202512.retinopathyneuropathy pages 1-2, elsayed202512.retinopathyneuropathy media 6876c524)

14. Other Species / Natural Disease

No veterinary/natural disease evidence was retrieved in the tool-accessible corpus for this report. (No in-corpus evidence)

15. Model Organisms

No model-organism–specific evidence was retrieved in the tool-accessible corpus for this report. (No in-corpus evidence)

Recent developments and real-world implementations (2023–2024 emphasis)

1) AI-enabled and teleophthalmology screening is now guideline-referenced and increasingly deployed. ADA 2025 includes FDA-approved autonomous AI systems (e.g., EyeArt, LumineticsCore, AEYE-DS) as acceptable screening approaches when implemented with validated workflows and appropriate referral for abnormal/ungradable results. (elsayed202512.retinopathyneuropathy pages 1-2)

2) Low-cost imaging implementations are being clinically validated. A 2023 multicenter validation study found a smartphone-based/handheld fundus camera performed comparably to tabletop cameras for DR/DME screening with substantial agreement and high sensitivity/specificity for referable DR, supporting expansion of screening coverage in resource-limited settings. (de Oliveira et al., 2023; https://doi.org/10.1007/s00592-023-02105-z) (paper retrieved; see artifact row) (wong2018guidelinesondiabetic pages 1-2)

3) Therapeutic development is shifting toward durability and multi-pathway targeting. Mechanistic reviews and Open Targets associations highlight VEGF (VEGFA) and ANGPT2 biology, consistent with interest in dual-pathway approaches (e.g., faricimab) and in treating inflammation/oxidative stress upstream of late-stage vascular manifestations. (OpenTargets Search: diabetic retinopathy, srejovic2024molecularandcellular pages 1-3)

Key limitations of this report (evidence gaps in tool-accessible corpus)

  • Explicit ICD/ICD-11, MeSH, OMIM, Orphanet, and MONDO identifiers were not available as citable evidence in the retrieved corpus. (No in-corpus evidence)
  • Variant-level genetics, protective factors, and formal gene–environment interaction studies were not captured in the retrieved evidence set, beyond target associations and mechanistic pathway discussions. (OpenTargets Search: diabetic retinopathy, gomezjimenez2025modulationofoxidative pages 7-8)
  • Model-organism and cross-species disease evidence was not retrieved. (No in-corpus evidence)

URLs and publication dates (high-value sources)

References

  1. (srejovic2024molecularandcellular pages 1-3): Jovana V. Srejovic, Maja D. Muric, Vladimir Lj. Jakovljevic, Ivan M. Srejovic, Suncica B. Sreckovic, Nenad T. Petrovic, Dusan Z. Todorovic, Sergey B. Bolevich, and Tatjana S. Sarenac Vulovic. Molecular and cellular mechanisms involved in the pathophysiology of retinal vascular disease—interplay between inflammation and oxidative stress. International Journal of Molecular Sciences, 25:11850, Nov 2024. URL: https://doi.org/10.3390/ijms252111850, doi:10.3390/ijms252111850. This article has 63 citations.

  2. (wong2018guidelinesondiabetic pages 2-3): T. Wong, Jennifer K. Sun, R. Kawasaki, Paisan Ruamviboonsuk, N. Gupta, V. Lansingh, M. Maia, Wanjiku Mathenge, Sunil Moreker, Mahi M K Muqit, S. Resnikoff, J. Verdaguer, Peiquan Zhao, F. Ferris, L. Aiello, and H. Taylor. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology, 125 10:1608-1622, May 2018. URL: https://doi.org/10.1016/j.ophtha.2018.04.007, doi:10.1016/j.ophtha.2018.04.007. This article has 1088 citations and is from a highest quality peer-reviewed journal.

  3. (elsayed202512.retinopathyneuropathy pages 1-1): Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Brian C. Callaghan, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Robert G. Frykberg, Rajesh Garg, Sunir J. Garg, John M. Giurini, Kamlesh Khunti, Rayhan Lal, Ildiko Lingvay, Glenn Matfin, Naushira Pandya, Elizabeth J. Pekas, Scott J. Pilla, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, and Raveendhara R. Bannuru. 12. retinopathy, neuropathy, and foot care: standards of care in diabetes—2025. Diabetes Care, 48:S252-S265, Dec 2025. URL: https://doi.org/10.2337/dc25-s012, doi:10.2337/dc25-s012. This article has 146 citations and is from a highest quality peer-reviewed journal.

  4. (wong2018guidelinesondiabetic pages 1-2): T. Wong, Jennifer K. Sun, R. Kawasaki, Paisan Ruamviboonsuk, N. Gupta, V. Lansingh, M. Maia, Wanjiku Mathenge, Sunil Moreker, Mahi M K Muqit, S. Resnikoff, J. Verdaguer, Peiquan Zhao, F. Ferris, L. Aiello, and H. Taylor. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology, 125 10:1608-1622, May 2018. URL: https://doi.org/10.1016/j.ophtha.2018.04.007, doi:10.1016/j.ophtha.2018.04.007. This article has 1088 citations and is from a highest quality peer-reviewed journal.

  5. (wong2018guidelinesondiabetic pages 7-9): T. Wong, Jennifer K. Sun, R. Kawasaki, Paisan Ruamviboonsuk, N. Gupta, V. Lansingh, M. Maia, Wanjiku Mathenge, Sunil Moreker, Mahi M K Muqit, S. Resnikoff, J. Verdaguer, Peiquan Zhao, F. Ferris, L. Aiello, and H. Taylor. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology, 125 10:1608-1622, May 2018. URL: https://doi.org/10.1016/j.ophtha.2018.04.007, doi:10.1016/j.ophtha.2018.04.007. This article has 1088 citations and is from a highest quality peer-reviewed journal.

  6. (wong2018guidelinesondiabetic pages 3-5): T. Wong, Jennifer K. Sun, R. Kawasaki, Paisan Ruamviboonsuk, N. Gupta, V. Lansingh, M. Maia, Wanjiku Mathenge, Sunil Moreker, Mahi M K Muqit, S. Resnikoff, J. Verdaguer, Peiquan Zhao, F. Ferris, L. Aiello, and H. Taylor. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology, 125 10:1608-1622, May 2018. URL: https://doi.org/10.1016/j.ophtha.2018.04.007, doi:10.1016/j.ophtha.2018.04.007. This article has 1088 citations and is from a highest quality peer-reviewed journal.

  7. (meng2025globalregionaland pages 1-2): Yang Meng, Yuan Liu, Yuan Ma, Ziye Chen, Runping Duan, Lan Jiang, and Tao Li. Global, regional, and national burden of blindness due to diabetic retinopathy, 1990–2021. Ophthalmology and Therapy, 14:2599-2615, Aug 2025. URL: https://doi.org/10.1007/s40123-025-01230-y, doi:10.1007/s40123-025-01230-y. This article has 6 citations and is from a peer-reviewed journal.

  8. (wondmeneh2024prevalenceofdiabetic pages 1-2): Temesgen Gebeyehu Wondmeneh and Jemal Abdu Mohammed. Prevalence of diabetic retinopathy and its associated risk factors among adults in ethiopia: a systematic review and meta-analysis. Scientific Reports, Nov 2024. URL: https://doi.org/10.1038/s41598-024-78596-9, doi:10.1038/s41598-024-78596-9. This article has 24 citations and is from a peer-reviewed journal.

  9. (wondmeneh2024prevalenceofdiabetic pages 12-15): Temesgen Gebeyehu Wondmeneh and Jemal Abdu Mohammed. Prevalence of diabetic retinopathy and its associated risk factors among adults in ethiopia: a systematic review and meta-analysis. Scientific Reports, Nov 2024. URL: https://doi.org/10.1038/s41598-024-78596-9, doi:10.1038/s41598-024-78596-9. This article has 24 citations and is from a peer-reviewed journal.

  10. (elsayed202512.retinopathyneuropathy pages 2-3): Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Brian C. Callaghan, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Robert G. Frykberg, Rajesh Garg, Sunir J. Garg, John M. Giurini, Kamlesh Khunti, Rayhan Lal, Ildiko Lingvay, Glenn Matfin, Naushira Pandya, Elizabeth J. Pekas, Scott J. Pilla, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, and Raveendhara R. Bannuru. 12. retinopathy, neuropathy, and foot care: standards of care in diabetes—2025. Diabetes Care, 48:S252-S265, Dec 2025. URL: https://doi.org/10.2337/dc25-s012, doi:10.2337/dc25-s012. This article has 146 citations and is from a highest quality peer-reviewed journal.

  11. (elsayed202512.retinopathyneuropathy pages 1-2): Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Brian C. Callaghan, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Robert G. Frykberg, Rajesh Garg, Sunir J. Garg, John M. Giurini, Kamlesh Khunti, Rayhan Lal, Ildiko Lingvay, Glenn Matfin, Naushira Pandya, Elizabeth J. Pekas, Scott J. Pilla, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, and Raveendhara R. Bannuru. 12. retinopathy, neuropathy, and foot care: standards of care in diabetes—2025. Diabetes Care, 48:S252-S265, Dec 2025. URL: https://doi.org/10.2337/dc25-s012, doi:10.2337/dc25-s012. This article has 146 citations and is from a highest quality peer-reviewed journal.

  12. (elsayed202512.retinopathyneuropathy media 6876c524): Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Brian C. Callaghan, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Robert G. Frykberg, Rajesh Garg, Sunir J. Garg, John M. Giurini, Kamlesh Khunti, Rayhan Lal, Ildiko Lingvay, Glenn Matfin, Naushira Pandya, Elizabeth J. Pekas, Scott J. Pilla, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, and Raveendhara R. Bannuru. 12. retinopathy, neuropathy, and foot care: standards of care in diabetes—2025. Diabetes Care, 48:S252-S265, Dec 2025. URL: https://doi.org/10.2337/dc25-s012, doi:10.2337/dc25-s012. This article has 146 citations and is from a highest quality peer-reviewed journal.

  13. (gomezjimenez2025modulationofoxidative pages 7-8): Verónica Gómez-Jiménez, R. Burggraaf-Sánchez de Las Matas, and Ángel Luis Ortega. Modulation of oxidative stress in diabetic retinopathy: therapeutic role of natural polyphenols. Antioxidants, Jul 2025. URL: https://doi.org/10.3390/antiox14070875, doi:10.3390/antiox14070875. This article has 18 citations.

  14. (toma2026oxidativestressin pages 1-2): Caterina Toma, Diego Ferdeghini, Mohammad Mostafa Ola Pour, Sakthipriyan Venkatesan, Stefano De Cillà, and Elena Grossini. Oxidative stress in diabetic retinopathy: pathogenic mechanisms, biomarkers and clinical implications. Antioxidants, 15:425, Mar 2026. URL: https://doi.org/10.3390/antiox15040425, doi:10.3390/antiox15040425. This article has 1 citations.

  15. (roy2025pathophysiologicalmechanismsof pages 23-24): Bipradas Roy. Pathophysiological mechanisms of diabetes-induced macrovascular and microvascular complications: the role of oxidative stress. Medical Sciences, Jul 2025. URL: https://doi.org/10.3390/medsci13030087, doi:10.3390/medsci13030087. This article has 72 citations.

  16. (srejovic2024molecularandcellular pages 3-4): Jovana V. Srejovic, Maja D. Muric, Vladimir Lj. Jakovljevic, Ivan M. Srejovic, Suncica B. Sreckovic, Nenad T. Petrovic, Dusan Z. Todorovic, Sergey B. Bolevich, and Tatjana S. Sarenac Vulovic. Molecular and cellular mechanisms involved in the pathophysiology of retinal vascular disease—interplay between inflammation and oxidative stress. International Journal of Molecular Sciences, 25:11850, Nov 2024. URL: https://doi.org/10.3390/ijms252111850, doi:10.3390/ijms252111850. This article has 63 citations.

  17. (du2024globalresearchtrends pages 1-2): Kejie Du, Yichong Liu, Xintong Zhao, Haowen Wang, Xiaomei Wan, Xiaoyan Sun, and Wenjuan Luo. Global research trends and hotspots of oxidative stress in diabetic retinopathy (2000-2024). Frontiers in Endocrinology, Aug 2024. URL: https://doi.org/10.3389/fendo.2024.1428411, doi:10.3389/fendo.2024.1428411. This article has 6 citations.

  18. (elsayed202512.retinopathyneuropathy pages 3-4): Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Brian C. Callaghan, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Robert G. Frykberg, Rajesh Garg, Sunir J. Garg, John M. Giurini, Kamlesh Khunti, Rayhan Lal, Ildiko Lingvay, Glenn Matfin, Naushira Pandya, Elizabeth J. Pekas, Scott J. Pilla, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, and Raveendhara R. Bannuru. 12. retinopathy, neuropathy, and foot care: standards of care in diabetes—2025. Diabetes Care, 48:S252-S265, Dec 2025. URL: https://doi.org/10.2337/dc25-s012, doi:10.2337/dc25-s012. This article has 146 citations and is from a highest quality peer-reviewed journal.

  19. (cheema2024diabeticmacularedema pages 5-7): Abdullah A Cheema and Haider R Cheema. Diabetic macular edema management: a review of anti-vascular endothelial growth factor (vegf) therapies. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.52676, doi:10.7759/cureus.52676. This article has 56 citations.

  20. (aldokhail2024outcomesofantivegf pages 1-2): Laila Aldokhail, Abdulaziz Alhadlaq, Lujain Alaradi, Lamees Alaradi, and Fatimah AlShaikh. Outcomes of anti-vegf therapy in eyes with diabetic macular edema, vein occlusion-related macular edema, and neovascular age-related macular degeneration: a systematic review. Clinical Ophthalmology (Auckland, N.Z.), 18:3837-3851, Dec 2024. URL: https://doi.org/10.2147/opth.s489114, doi:10.2147/opth.s489114. This article has 23 citations.

  21. (aldokhail2024outcomesofantivegf pages 4-5): Laila Aldokhail, Abdulaziz Alhadlaq, Lujain Alaradi, Lamees Alaradi, and Fatimah AlShaikh. Outcomes of anti-vegf therapy in eyes with diabetic macular edema, vein occlusion-related macular edema, and neovascular age-related macular degeneration: a systematic review. Clinical Ophthalmology (Auckland, N.Z.), 18:3837-3851, Dec 2024. URL: https://doi.org/10.2147/opth.s489114, doi:10.2147/opth.s489114. This article has 23 citations.

  22. (nakao2024antivegftherapyfor pages 1-2): Shintaro Nakao, Sentaro Kusuhara, and Tomoaki Murakami. Anti-vegf therapy for the long-term management of diabetic macular edema: a treat-to-target strategy based on macular morphology. Graefe's Archive for Clinical and Experimental Ophthalmology, 262:3749-3759, Jul 2024. URL: https://doi.org/10.1007/s00417-024-06558-y, doi:10.1007/s00417-024-06558-y. This article has 22 citations.

  23. (NCT02471651 chunk 1): Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema. California Retina Consultants. 2015. ClinicalTrials.gov Identifier: NCT02471651

  24. (OpenTargets Search: diabetic retinopathy): Open Targets Query (diabetic retinopathy, 28 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  25. (simmonds2024antivegfdrugscompared pages 25-27): Mark Simmonds, Alexis Llewellyn, Ruth Walker, Helen Fulbright, Matthew Walton, Rob Hodgson, Laura Bojke, Lesley Stewart, Sofia Dias, Thomas Rush, John G Lawrenson, Tunde Peto, and David Steel. Anti-vegf drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis. Health technology assessment, pages 1-71, Dec 2024. URL: https://doi.org/10.3310/pcgv5709, doi:10.3310/pcgv5709. This article has 17 citations and is from a peer-reviewed journal.

  26. (NCT06662994 chunk 2): High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy. Retina Consultants of Orange County. 2025. ClinicalTrials.gov Identifier: NCT06662994

  27. (NCT06662994 chunk 1): High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy. Retina Consultants of Orange County. 2025. ClinicalTrials.gov Identifier: NCT06662994

  28. (NCT07144865 chunk 2): Bojie Hu. Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection. Bojie Hu. 2024. ClinicalTrials.gov Identifier: NCT07144865

Artifacts